158 related articles for article (PubMed ID: 38773761)
1. A Network Meta-Analysis of the Systemic Therapies in Unresectable Head and Neck Squamous Cell Carcinoma.
Yuan J; Shi K; Chen G; Xu W; Qiu L; Fei Y; Zhu Y; Wu M; Li Y; Sun X; Cao Y; Zhou S
Cancer Control; 2024; 31():10732748241255535. PubMed ID: 38773761
[TBL] [Abstract][Full Text] [Related]
2. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
[TBL] [Abstract][Full Text] [Related]
3. A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN)☆.
Jerzak KJ; Delos Santos K; Saluja R; Lien K; Lee J; Chan KKW
Oral Oncol; 2017 Aug; 71():1-10. PubMed ID: 28688674
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review.
Winquist E; Agbassi C; Meyers BM; Yoo J; Chan KKW;
J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):29. PubMed ID: 28376866
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
[TBL] [Abstract][Full Text] [Related]
9. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis.
Yan M; Kumachev A; Siu LL; Chan KK
Eur J Cancer; 2015 Aug; 51(12):1570-9. PubMed ID: 26044925
[TBL] [Abstract][Full Text] [Related]
10. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316
[TBL] [Abstract][Full Text] [Related]
11. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer.
Okano S; Enokida T; Onoe T; Ota Y; Motegi A; Zenda S; Akimoto T; Tahara M
Int J Clin Oncol; 2019 Jul; 24(7):789-797. PubMed ID: 30796560
[TBL] [Abstract][Full Text] [Related]
12. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis.
Ribassin-Majed L; Marguet S; Lee AWM; Ng WT; Ma J; Chan ATC; Huang PY; Zhu G; Chua DTT; Chen Y; Mai HQ; Kwong DLW; Cheah SL; Moon J; Tung Y; Chi KH; Fountzilas G; Bourhis J; Pignon JP; Blanchard P
J Clin Oncol; 2017 Feb; 35(5):498-505. PubMed ID: 27918720
[TBL] [Abstract][Full Text] [Related]
13. Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas.
Petit C; Blanchard P; Pignon JP; Lueza B
Syst Rev; 2019 Apr; 8(1):96. PubMed ID: 30987679
[TBL] [Abstract][Full Text] [Related]
14. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.
Fang L; Shi L; Wang W; Hu T; Rao X
Eur Arch Otorhinolaryngol; 2021 Oct; 278(10):3633-3642. PubMed ID: 33598731
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis.
Zhang L; Jiang N; Shi Y; Li S; Wang P; Zhao Y
Sci Rep; 2015 Jun; 5():10798. PubMed ID: 26041604
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
[TBL] [Abstract][Full Text] [Related]
17. The Changing Therapeutic Role of Chemo-radiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma from Two/Three-Dimensional Radiotherapy to Intensity-Modulated Radiotherapy: A Network Meta-Analysis.
You R; Cao YS; Huang PY; Chen L; Yang Q; Liu YP; Zou X; Zhang YN; Jiang R; Zhang MX; Duan CY; Lin AH; Hong MH; Chen MY
Theranostics; 2017; 7(19):4825-4835. PubMed ID: 29187906
[No Abstract] [Full Text] [Related]
18. The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis.
Zhan ZJ; Yao WY; Zhang F; Qiu WZ; Liao K; Feng JH; Tan JY; Liu H; Yuan TZ; Zheng RH; Yuan YW
Front Immunol; 2021; 12():719650. PubMed ID: 34413862
[TBL] [Abstract][Full Text] [Related]
19. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis.
Tang WH; Sun W; Long GX
Medicine (Baltimore); 2020 Sep; 99(36):e21785. PubMed ID: 32899005
[TBL] [Abstract][Full Text] [Related]
20. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
Zandberg DP; Cullen K; Bentzen SM; Goloubeva OG
Oral Oncol; 2018 Nov; 86():132-140. PubMed ID: 30409293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
